Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the head and neck meeting the following criteria:~  * Site of tumor origin in the oral cavity, oropharynx, larynx, or hypopharynx (excluding lip, nasopharynx, or sinuses)~ * Gross total resection must be completed within 7 weeks of randomization, with pathology demonstrating one or more of the following risk factors:~    * Histologic extracapsular nodal extension~   * Histologic involvement of ≥ 2 regional lymph nodes~   * Invasive cancer seen on microscopic evaluation of the resection margin, with no evidence of gross tumor residual.~   * Tonsillar cancer patients who undergo transoral excision of all gross tumor are eligible provided extracapsular nodal extension or involvement of ≥ 2 regional lymph nodes is histologically confirmed~ * American Joint Committee on Cancer (AJCC) pathological stage III or IV~* No evidence of distant metastases~* No synchronous or concurrent head and neck primary tumors~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin \> 8.0 g/dL~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT), and alkaline phosphatase meeting 1 of the following parameters:~  * Alkaline phosphatase ≤ ULN AND AST or ALT ≤ 5 times ULN~ * Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~ * Alkaline phosphatase ≤ 5 times ULN AND AST or ALT ≤ ULN~Renal~* Creatinine ≤ 1.5 mg/dL~Cardiovascular~* No unstable angina~* No uncontrolled hypertension~* No myocardial infarction within the past 6 months (unless successfully treated with coronary artery bypass surgery or percutaneous transluminal coronary angioplasty)~* No uncontrolled arrhythmia~* No congestive heart failure~* No more than 2 heart-related hospitalizations within the past year~* No other active cardiac disease~Pulmonary~* No more than 2 hospitalizations for chronic obstructive pulmonary disease within the past year~Neurologic~* No pre-existing peripheral neuropathy ≥ grade 2~* No uncontrolled seizure disorder~* No active neurological disease~Other~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No other invasive malignancy within the past 3 years except nonmelanoma skin cancer~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior anti-epidermal growth factor receptor antibody therapy~Chemotherapy~* More than 3 years since prior cytotoxic chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior head and neck radiotherapy~Surgery~* See Disease Characteristics~Other~* No prior tyrosine kinase inhibitor therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RT + cisplatin + cetuximab (Type: EXPERIMENTAL): Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
- RT + docetaxel + cetuximab (Type: EXPERIMENTAL): Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).